Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
Arcturus Therapeutics Holdings Inc. (ARCT)
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arcturusrx.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, May 20, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Pad Chivukula, Ph.D., Chief Scientific and Chief Operating Officer of Arcturus, will present data for ARCT-810 along with data for the Company’s mRNA + LUNAR® platform in a presentation titled “LUNAR®: Enabling Delivery of mRNA Therapeutics and Vaccines” at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics, being held May 20-23, 2019 in San Diego, California. “Arcturus is fortunate to have a team of talented scientists that continue to generate quality data through rigorous science and innovation,” said Dr. Chivukula. “I look forward to sharing the progress we have made on ARCT-810 and additional data for the growing Arcturus mRNA therapeutics platform enabled by LUNAR.” Arcturus is presenting the fo
Show less
Read more
Impact Snapshot
Event Time:
ARCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARCT alerts
High impacting Arcturus Therapeutics Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ARCT
News
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
- Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Arcturus Therapeutics Reports Fiscal Year 2023 Financial Results and Pipeline Developments [Yahoo! Finance]Yahoo! Finance
ARCT
Earnings
- 3/7/24 - Beat
ARCT
Sec Filings
- 4/5/24 - Form 8-K
- 4/5/24 - Form SC
- 3/27/24 - Form 4
- ARCT's page on the SEC website